General Dermatology

Ablon covered all aspects of getting involved in clinical research, such as budgeting, recruiting, and analyzing data.

Maximize your AAD 2025 experience with expert tips on education, networking, and navigating the exhibit hall in Orlando.

Start the new year with a look at top dermatology conferences, expert insights, and the latest research on pigmentary disorders, psoriasis, and antiaging treatments.

Answer today’s poll and read more about the validity of dermatological content being shared on TikTok.

The clinically-backed, post-procedure sunscreen is designed to enhance skin healing, reduce redness, promote hydration, and provide broad-spectrum UV protection.

Explore the top headlines of the week including innovation in scalp treatment, therapeutic updates in rosacea, and acne vulgaris insights from James Del Rosso, DO.

In case you missed it, this week we had news about awareness resources from the Skin Cancer Foundation, burn care disparities in skin of color, aesthetic insights for patients on medication-driven weight loss journeys, and more.

Learn more about the in-depth topics covered in the January 2025 print issue of Dermatology Times.

Dermatology Times is looking back on the top stories in dermatology from the month of January.

Dermatology Times is recapping our top expert interviews from the month of January.

James Del Rosso, DO, shared insights on existing and upcoming therapies for seborrheic dermatitis.

Explore the top headlines of the week including clinical trial updates, social media hair trends, and expert insights.

In case you missed it, this week we had news about the link between psoriasis and dementia, the future of urticaria treatment, VP-315's positive results in basal cell carcinoma, and more.

Personalized care is key to managing hyperhidrosis, blending therapies, addressing adverse effects, and empowering patients with tailored solutions.

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

According to a phase 3 study, the omalizumab biosimilar saw comparable results with a good safety profile.

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Attovia is also advancing 4 ATTOBODY-based programs for inflammatory conditions, such as atopic dermatitis and IBD.

Adam Friedman, MD, FAAD, takes a closer look at the emerging landscape of oral treatments for hyperhidrosis and what lies ahead in advancing patient care.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Explore the top headlines of the week including the growth of NPs and PAs in the field, clinical trial updates, and advancements in therapy.

In case you missed it, this week we had news about AIs and CNNs for early melanoma detection, OCT Technology for vitiligo imaging, UCB’s 320mg single-injection bimekizumab, and more.

A recent study evaluated the efficacy of low-energy delicate pulsed light photomodulation for treating sensitive skin, showing significant improvements in symptoms and erythema.